Abstract | OBJECTIVE: CASE SUMMARY: DISCUSSION:
Amantadine is a noncompetitive N-methyl d-aspartate receptor antagonist. It is mainly used in the treatment of Parkinson's disease, as it increases dopamine levels in the brain. This effect is said to ameliorate akinesia. Although the effect of amantadine on choreatic dystonia in HD has been reported in several studies, to the best of our knowledge, this is the first report of the ameliorative effects of amantadine on the rigid form of HD. Our patient showed improvements of gait, parkinsonism, and dystonia. Fine-motor tasks and eye movement did not change significantly. CONCLUSIONS: We suggest that amantadine treatment might be of value to patients with the akinetic-rigid variant of HD.
|
Authors | Markus K Magnet, Raphael M Bonelli, Hans-Peter Kapfhammer |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
2004 Jul-Aug
Vol. 38
Issue 7-8
Pg. 1194-6
ISSN: 1060-0280 [Print] United States |
PMID | 15178736
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antiparkinson Agents
- Amantadine
|
Topics |
- Adult
- Amantadine
(therapeutic use)
- Antiparkinson Agents
(therapeutic use)
- Female
- Humans
- Huntington Disease
(drug therapy)
|